ANEW MEDICAL INC’s leadership team is comprised of individuals who are dedicated to upholding the company’s core principles of cutting-edge technology, quality, and integrity. We will produce and sell products with the highest quality we expect for ourselves, our children and our family and friends. This was the key driving principle for the formation of the company and its ongoing operations.

Our dedicated team is comprised of individuals with the technical, biopharmaceutical manufacturing, gene therapy, cell therapy, clinical, regulatory, and business expertise that is necessary for innovation and success. The combination of this experience will contribute to the development of a diverse range of life-saving medicines. Our staffing includes personnel and advisors in the U.S. and Europe that have extensive experience in the “branded” pharmaceutical and biotechnology commercial processes for making and selling biologic-based drugs. The Company will exploit its technical and commercial expertise to develop and obtain approval to launch, market and sell our own branded product lines, and/or to develop partnerships with other large pharmaceutical corporations to market and sell our products.

Dr. Joseph Sinkule

Founder, Chief Executive Officer (CEO), Director and Chairman of the Board

Dr. Sinkule is the company’s Chief Executive Officer (CEO), Founder, and the Chairman of the Board of Directors. He has over 40 years of drug, biologic, and medical device R&D and commercialization experience. This serial entrepreneur is the founder and driving force behind the Company, its growing product portfolio, and its financing strategies. He has personally managed over 8 drug and biotech products successfully through FDA approval to market, 5 medical devices and 8 in vitro diagnostics. He has hired and managed both small and large teams of experienced people in pharma and biotech organizations, and managed contract research organizations (“CROs”) and contract development and manufacturing companies (“CDMOs”), working for large and small clients. After serving in academics and then in industry, Dr. Sinkule has evolved into a successful businessman and entrepreneur. He serves on the Board of two companies, and routinely consults for venture capitalist firms, investment banks, as well as both large and early-stage pharmaceutical and biotech companies.

Mr. Peter Moriarty

Chief Operating Officer

Peter Moriarty is the company’s Chief Operating Officer (COO) and has extensive experience in the pharmaceutical industry both in the United States and internationally. He was a co-founder of Shire Pharmaceuticals, an international specialty pharmaceutical company acquired by Takeda Pharmaceuticals (TAK: NASDAQ). Until its acquisition, Peter was the Executive Chairman of Prismic Pharmaceuticals, a specialty pharmaceutical company he co-founded in 2011, and where he was also the CEO from 2013 to 2018. Prismic was acquired by FSD Pharma (HUGE: NASDAQ). Peter’s earlier career spanned management positions within Warner-Lambert/ Parke-Davis and Schering- Plough, including leadership positions overseas as well as in the United States. Additionally, he led the Sales Force Automation and Software Products Division at Walsh America (acquired by NDC), and led Corporate Development at Ixsys /Applied Molecular Evolution acquired by Eli Lilly (LLY – NYSE). He was subsequently the founder, Chairman and Chief Executive Officer of iPhysicianNet, Inc. and Clinical Information Network.

Mr. Edward Cong Wang

Chief Financial Officer and Director

Mr. Edward Cong Wang is the company’s Chief Financial officer (CFO) and a member of our Board of Directors. He has extensive financial management experience and expertise. He was the Chief Financial of Officer of Redwoods Acquisition Corporation until Redwoods merger with ANEW MEDICAL, Inc. Mr. Cong Wang’s career includes leading Pacifico Acquisition Corp. (NASDAQ: PAFO), serving as managing partner at The Balloch (Holding) Group, a partner at Shenzhen Bode Chuangfu Investment Management Co. Ltd, and the CEO of a family owned business. Earlier in his career, Mr. Cong Wang worked as a Vice President at Merrill Lynch, Pierce, Fenner & Smith, Inc. In 2006, he received a bachelor’s degree in Economics/Finance from Stony Brook State University, and in 2010 graduated with a master’s degree in Statistics from Columbia University in 2010.

Dr. Miguel Chillón Rodriguez

Chief Scientific Officer and Consultant

Professor Dr. Chillon is the inventor of the α-Klotho patents and technology know how. He has over 25 years of research experience in several key areas of α-klotho and adeno-associated virus (“AAV”) packaging and gene delivery. Miguel has several associates that work with him to expedite development and further the intellectual properties and scientific publications. He leads the research group on Gene therapy for CNS diseases at Universitat Autonoma De Barcelona and Institucio Catalana De Recerca I Estudis Avancats. Miguel is also the Director of the Viral Vector Production Unit at Vall d’Hebrón Hospital, and serves Chair of the ATMP Platform of European Infrastructure for Translational Medicine

Dr. Shalom Hirshman

Chief Medical Officer, Emeritus, and Director

Dr. Shalom Hirschman, M.D. is a Founder of the company and a preeminent research physician, a clinical medical expert, and entrepreneur in infectious diseases, oncology, and cancer supportive care. He is a key consulting advisor to the Company. As a young man, he served as an intern and resident in medicine at the Massachusetts General Hospital and Harvard Medical School, and then went on to a career in molecular biology and virology research at the National Institute of Health (NIH). During his career in medical research, he interacted closely with several Nobel Prize winners including Drs. Berson and Yalow (Nobel Prize for development of radioimmunoassays). He was recruited to The Mount Sinai School of Medicine and The Mount Sinai Hospital in New York City as Head of the Department of Infectious Diseases, and eventually he also became Vice-Chairman and Chairman of the Department of Medicine at Mount Sinai, where he remained for three decades. He still is asked to consult on difficult diagnostic dilemmas like the recent COVID-19 pandemic.

Dr. Samuel Zentman

Independent Director

Dr. Zentman graduated from Wayne State University and the University of Michigan and holds a Ph.D. doctorate in Complex Analysis. He was a Mathematics professor at several divisions of the University of Detroit. And worked as a systems analyst, manager of Engineering Computer Center, and director of the Corporate Computer Center of American Motors Corporation. Dr. Zentman was the CFO and then CEO of Manhattan Textile Corporation, a privately held export firm in New York city. He was a Board member of several Tech and Medical start-ups including: Neuromedical Systems Inc., Amplification Technologies, Inc., Power Safe Technology Corp, and Hinson Hale Medical Technologies Inc. Sam is currently a Board member of Acorn Energy where he has serv3ed for over the past 15 years, and is the Chairman of the Audit Committee, and member of the Nominating Committee and Compensation Committee. Sam has extensive experience in dealing with early stage medical and technology companies. He also serves as the Chairman of the Board of several national non-profits organizations devoted to the quality of education in the U.S. and abroad. We believe Dr. Zentman is qualified to serve on our Board because of his decades of expertise in business management, public and private company finance, his insight in medical technologies, and his global contacts and business relationships.

Mr. Jon McGarity

Independent Director

Mr. McGarity is the President & CEO of EthiX Associates, which he founded in February 1996 and is a consultancy business serving the business needs of the healthcare industry with a focus on pharmaceuticals and biotechnology. In addition, he has been the Chief Operating Officer of MiClimate, Inc. since 2022 which has developed the first body temperature regulation device resulting in a change in the way people manage individual temperature sensitivities. He co-founded NeuroEM Therapeutics, Inc., which is currently evaluating transcranial electromagnetic therapy (TEMT) for the treatment of cognitive functioning in Alzheimer’s disease patients, and has been its Chief Business Officer since 2021. In addition he currently is an Advisor to the Biodesign Institute at Arizona State University. He is an original and current member of the Arizona Biosciences Roadmap Committee which provides strategic direction to the biosciences industry in Arizona. His pharmaceutical experience includes senior management positions with GlaxoSmithKline, Bristol Myers Squibb and Novartis (Sandoz Pharmaceuticals). Mr. McGarity has launched over 40 products as well as completing numerous business development deals involving product acquisitions, licensing, co-marketing and promotional arrangements. Mr. McGarity’s experience having held executive positions at “big pharma” companies, start-up operations, drug and biologics regulations, marketing and sales, and finance makes him qualified to serve as a director.

Edward Cong Wang

Director and Chief Financial Officer (CFO)

Mr. Wang is the company’s Chief Financial Officer (CFO) and the former CFO of Redwoods Acquisition Corp prior to it’s business combination with ANEW. He has served as the Chairman, President and Chief Executive Officer at Pacifico Acquisition Corp. (NASDAQ: PAFO) since March 2021, and has also served as the managing partner at The Balloch (Holding) Group since March 2020. Before that, he was a partner at Prestige Financial Holdings Group Limited from August 2018 to September 2019. Mr. Wang served as a partner at Shenzhen Bode Chuangfu Investment Management Co. Ltd., from January 2017 to July 2018. Mr. Wang served as the chief executive officer of ZS Fur & Leather Fashion Co., a family owned business, from July 2014 to December 2016. Prior to ZS Fur, he worked at Merrill Lynch, Pierce, Fenner & Smith Incorporated as a vice president from July 2011 to June 2014. Mr. Wang received a bachelor’s degree in Economics/Finance from Stony Brook State University in 2006 and graduated with a master’s degree of Statistics from Columbia University in 2010. We believe Mr. Wang is qualified to serve on our Board because of his extensive financial, management, and transaction experience, as well as his contacts and relationships.

Board of Directors

Dr. Joseph Sinkule

CEO and Chairman of the Board of Directors

Dr. Shalom Hirschman


Dr. Samuel Zentman

Independent Director

Jon McGarity

Independent Director

Edward Cong Wang

Chief Financial Officer (CFO) and Director